| 2026-09-14 | 8-K | Form 8-K, Item 8.01 |
| 2026-09-01 | Press release | Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals |
| 2026-08-24 | 10-K | Annual report on Form 10-K, FY26 |
| 2026-08-13 | Press release | Bio-Techne Corrects Dividend Announcement · Q2 2026 |
| 2026-08-12 | Press release | Bio-Techne Declares Dividend |
| 2026-08-12 | Press release | Bio-Techne Releases Fourth Quarter Fiscal 2026 Results |
| 2026-08-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-08 | Press release | Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows |
| 2026-06-26 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-25 | Press release | Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets |
| 2026-06-25 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-04 | Press release | Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization |
| 2026-05-06 | Press release | Bio-Techne Declares Dividend |
| 2026-05-06 | Press release | Bio-Techne Releases Third Quarter Fiscal 2026 Results |
| 2026-05-06 | Press release | Earnings Release · Q3 2026 |
| 2026-05-06 | Press release | PDF: Bio-Techne Releases Third Quarter Fiscal 2026 Results |
| 2026-05-06 | Press release | Press release · Q3 2026 · May 2026 |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-06 | Transcript | Q3 FY26 earnings call transcript |
| 2026-05-04 | Press release | Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference |
| 2026-04-16 | Press release | Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity |
| 2026-04-14 | Press release | Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results |
| 2026-03-25 | Press release | Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite |
| 2026-02-24 | Press release | Bio-Techne to Present at Upcoming Investor Conferences |
| 2026-02-16 | Press release | Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories |
| 2026-02-11 | Press release | Bio-Techne Announces Changes to its Leadership Team |
| 2026-02-11 | 8-K | Form 8-K, Item 5.02 |
| 2026-02-04 | Press release | Bio-Techne Declares Dividend |
| 2026-02-04 | Press release | Bio-Techne Releases Second Quarter Fiscal 2026 Results |
| 2026-02-04 | Press release | Earnings Release · Q2 2026 |
| 2026-02-04 | Press release | PDF: Bio-Techne Releases Second Quarter Fiscal 2026 Results |
| 2026-02-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-04 | 10-Q | Form 10-Q for the quarter ended Dec 31 |
| 2026-02-04 | Transcript | Q2 FY26 earnings call transcript |
| 2026-02-02 | Press release | Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative |
| 2026-01-28 | Press release | Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers |
| 2026-01-20 | Press release | Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results |
| 2026-01-01 | Deck | Investor presentation · Jan 2026 |
| 2025-11-05 | Press release | PDF: Bio-Techne Releases First Quarter Fiscal 2026 Results |